Subsequent Events

9 Months Ended

Sep. 30, 2021

Subsequent Events [Abstract]

Subsequent Events

Note O – Subsequent Events

At the Market Offerings

During the period of October 1, 2021 through November 5, 2021, we received net proceeds of approximately $50.2 million from the sale of approximately 9.2 million shares of our common stock under the Sales Agreement.

MiNK Therapeutics Initial Public Offering

In October 2021, our affiliate, MiNK Therapeutics completed an initial public offering of 3,333,334 shares of its common stock, trading on the Nasdaq Global Market under the ticker symbol “INKT”, at a public offering price of $12.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $40.0 million. Following the completion of the initial public offering, the underwriters exercised their option to acquire 500,000 more shares of MiNK Therapeutics common stock at the initial offering price, which shares were issued on November 3, 2021. We own 26,332,958 shares, representing 78.6% of MiNK Therapeutics’ common stock.